# Novel platform for research brain banking and characterization using integrated traditional and quantitative analyses to promote precision neuropathology of Alzheimer's disease

> **NIH NIH U19** · ALLEN INSTITUTE · 2022 · $1,238,307

## Abstract

ABSTRACT (PROJECT 1)
The underlying goal of Project 1 is to facilitate an integrated neuropathological approach incorporating
traditional and quantitative pathology techniques with cell-type and molecular profiling to develop a unique
resource to promote next generation AD research. It leverages existing collaborative relationships between
UW Neuropathology and the UW ADRC and Kaiser Adult Changes in Thought studies for research autopsies.
Project 1 will implement newly developed protocols for modernized autopsy sampling and preservation of brain
tissue that are amenable to state-of-the-art cell type and molecular profiling techniques (Aim 1), as planned in
Projects 2 and 3. Deceased subjects from both studies with short post-mortem intervals will enter Project 1
tissue pipeline to ensure high quality tissue preservation and availability for -omics Projects, with appropriate
quality control measures at each step. Each ACT and ADRC autopsy includes qualitative neuropathological
examination with extensive sampling and a battery of immunostains specific to pathologic peptides according
to the latest guidelines. Neuropathological data from each case will be reviewed at regular meetings with
Project 1 investigators; cases along the spectrum of AD pathology, but lacking co-morbid neuropathologies,
will be promoted to eligibility for inclusion in Aim 2 and the Projects 2 and 3 pipelines. Aim 2 expands analysis
of selected cases to include all regions of interest for Projects 2 and 3, but also regions of relevance to current
AD cognitive subtypes and biomarker studies with a battery of immunohistochemical stains, image analysis,
and quantitative assays to characterize neurodegeneration (pathologic peptides), neurotoxicity (neurons,
synaptic markers, stains for white matter and oxidative stress), and reactivity (astrocytes, microglia,
inflammation). In Aim 3, results from cell-type and molecular profiling studies in Projects 2 and 3 will be
prioritized for targets identified in early AD pathogenesis, validated, and extended to the broader autopsy
cohort to determine relevance. Quantitative measures for these analyses may include Luminex-based
immunoassays and other techniques proteins and metabolites of neurodegeneration, neurotoxicity, and
neuroinflammation/gliosis in regions and subjects of interest. We predict, based on the last five years,
approximately 30 cases per year that are eligible for inclusion in Aim 2 and Project 2 and 3 pipelines. Each
brain that goes through Project 1 pipeline, even if not selected for inclusion in the -omics components of the
Center, will be preserved according to these novel protocols and deeply characterized for future studies of AD
subtypes, risk variants, related disorders, and exposure profiles.

## Key facts

- **NIH application ID:** 10375360
- **Project number:** 5U19AG060909-03
- **Recipient organization:** ALLEN INSTITUTE
- **Principal Investigator:** CHRISTOPHER DIRK KEENE
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1,238,307
- **Award type:** 5
- **Project period:** 2020-03-01 → 2025-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10375360

## Citation

> US National Institutes of Health, RePORTER application 10375360, Novel platform for research brain banking and characterization using integrated traditional and quantitative analyses to promote precision neuropathology of Alzheimer's disease (5U19AG060909-03). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10375360. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*